- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06307665
Evaluering av effektiviteten og sikkerheten til PT027 sammenlignet med PT007 administrert etter behov hos deltakere 12 til <18 år med astma (ACADIA)
En randomisert, dobbeltblind, multisenter, parallell gruppe, fase IIIb 52 ukers studie som evaluerer effektiviteten og sikkerheten til PT027 sammenlignet med PT007 administrert etter behov hos deltakere 12 til < 18 år med astma (ACADIA)
The purpose of this study is to compare the effect of budesonide/albuterol metered-dose inhaler (BDA MDI) with albuterol sulfate metered-dose inhaler (AS MDI), both administered as needed, on the annualized rate of severe asthma exacerbations in adolescents with a documented clinical diagnosis of asthma and at least one severe exacerbation in the prior year.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
This is a randomized, double-blind, multicenter, parallel-group Phase IIIb study with a fixed treatment period of 52 weeks.
The study will consist of 3 periods:
- Screening period (7 to 28 days)
- Treatment period of 52 weeks
- Safety follow-up period (7 to 14 days after the end of treatment [EOT] visit)
Participants who meet the eligibility criteria will be randomly assigned to BDA MDI 160/180 micrograms (μg) or AS MDI 180 μg treatment groups in a 1:1 ratio on top of their own usual maintenance therapy during treatment period.
This study will also include a pharmacokinetic (PK) sub-study with single visit scheduled after the safety follow-up visit in the main study. During PK sub-study, single dose of open-label BDA MDI 160/180 μg will be administered.
Studietype
Registrering (Antatt)
Fase
- Fase 3
Kontakter og plasseringer
Studiekontakt
- Navn: AstraZeneca Clinical Study Information Center
- Telefonnummer: 1-877-240-9479
- E-post: information.center@astrazeneca.com
Studiesteder
-
-
Alaska
-
Anchorage, Alaska, Forente stater, 99508
- Rekruttering
- Research Site
-
-
Arizona
-
Gilbert, Arizona, Forente stater, 85234
- Rekruttering
- Research Site
-
Phoenix, Arizona, Forente stater, 85016
- Rekruttering
- Research Site
-
-
Arkansas
-
Little Rock, Arkansas, Forente stater, 72202
- Fullført
- Research Site
-
-
California
-
Huntington Beach, California, Forente stater, 92647
- Har ikke rekruttert ennå
- Research Site
-
Huntington Beach, California, Forente stater, 92648
- Har ikke rekruttert ennå
- Research Site
-
Long Beach, California, Forente stater, 90806
- Rekruttering
- Research Site
-
Long Beach, California, Forente stater, 90815
- Rekruttering
- Research Site
-
Madera, California, Forente stater, 93636
- Har ikke rekruttert ennå
- Research Site
-
Mission Viejo, California, Forente stater, 92691
- Rekruttering
- Research Site
-
Moreno Valley, California, Forente stater, 92553
- Rekruttering
- Research Site
-
Orange, California, Forente stater, 92868
- Rekruttering
- Research Site
-
Redondo Beach, California, Forente stater, 90277
- Rekruttering
- Research Site
-
Riverside, California, Forente stater, 92506
- Rekruttering
- Research Site
-
San Diego, California, Forente stater, 92123
- Har ikke rekruttert ennå
- Research Site
-
San Diego, California, Forente stater, 92123
- Rekruttering
- Research Site
-
San Francisco, California, Forente stater, 94143
- Tilbaketrukket
- Research Site
-
Westminster, California, Forente stater, 92683
- Rekruttering
- Research Site
-
-
Colorado
-
Denver, Colorado, Forente stater, 80206
- Rekruttering
- Research Site
-
-
Delaware
-
Wilmington, Delaware, Forente stater, 19803
- Rekruttering
- Research Site
-
-
Florida
-
Destin, Florida, Forente stater, 32541
- Rekruttering
- Research Site
-
Jacksonville, Florida, Forente stater, 32207
- Rekruttering
- Research Site
-
Kendall, Florida, Forente stater, 33176
- Har ikke rekruttert ennå
- Research Site
-
Largo, Florida, Forente stater, 33777
- Fullført
- Research Site
-
Miami, Florida, Forente stater, 33144
- Rekruttering
- Research Site
-
Miami, Florida, Forente stater, 33145
- Rekruttering
- Research Site
-
Miami, Florida, Forente stater, 33185
- Rekruttering
- Research Site
-
Miami, Florida, Forente stater, 33142
- Rekruttering
- Research Site
-
Miami, Florida, Forente stater, 33183
- Rekruttering
- Research Site
-
Orlando, Florida, Forente stater, 32827
- Har ikke rekruttert ennå
- Research Site
-
Pembroke Pines, Florida, Forente stater, 33026
- Rekruttering
- Research Site
-
Tampa, Florida, Forente stater, 33613
- Tilbaketrukket
- Research Site
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30329
- Rekruttering
- Research Site
-
Columbus, Georgia, Forente stater, 31904
- Rekruttering
- Research Site
-
Fayetteville, Georgia, Forente stater, 30214
- Rekruttering
- Research Site
-
Snellville, Georgia, Forente stater, 30078
- Rekruttering
- Research Site
-
-
Idaho
-
Meridian, Idaho, Forente stater, 83646
- Tilbaketrukket
- Research Site
-
-
Illinois
-
Normal, Illinois, Forente stater, 61761
- Rekruttering
- Research Site
-
River Forest, Illinois, Forente stater, 60305
- Tilbaketrukket
- Research Site
-
-
Indiana
-
Indianapolis, Indiana, Forente stater, 46202
- Rekruttering
- Research Site
-
-
Kansas
-
Kansas City, Kansas, Forente stater, 66160
- Rekruttering
- Research Site
-
Overland Park, Kansas, Forente stater, 66213
- Har ikke rekruttert ennå
- Research Site
-
-
Kentucky
-
Louisville, Kentucky, Forente stater, 40217
- Rekruttering
- Research Site
-
Louisville, Kentucky, Forente stater, 40202
- Rekruttering
- Research Site
-
-
Louisiana
-
Lafayette, Louisiana, Forente stater, 70508
- Rekruttering
- Research Site
-
New Orleans, Louisiana, Forente stater, 70121
- Rekruttering
- Research Site
-
New Orleans, Louisiana, Forente stater, 70125
- Rekruttering
- Research Site
-
-
Maryland
-
Ellicott City, Maryland, Forente stater, 21043
- Rekruttering
- Research Site
-
Lanham, Maryland, Forente stater, 20706
- Har ikke rekruttert ennå
- Research Site
-
Silver Spring, Maryland, Forente stater, 20902
- Rekruttering
- Research Site
-
White Marsh, Maryland, Forente stater, 21162
- Rekruttering
- Research Site
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02114
- Har ikke rekruttert ennå
- Research Site
-
-
Michigan
-
Detroit, Michigan, Forente stater, 48201
- Rekruttering
- Research Site
-
-
Minnesota
-
Mankato, Minnesota, Forente stater, 56001
- Aktiv, ikke rekrutterende
- Research Site
-
-
Missouri
-
Kansas City, Missouri, Forente stater, 64118
- Rekruttering
- Research Site
-
Kansas City, Missouri, Forente stater, 64108
- Tilbaketrukket
- Research Site
-
St Louis, Missouri, Forente stater, 63108
- Rekruttering
- Research Site
-
-
Montana
-
Missoula, Montana, Forente stater, 59804
- Rekruttering
- Research Site
-
-
Nebraska
-
Lincoln, Nebraska, Forente stater, 68510
- Rekruttering
- Research Site
-
Lincoln, Nebraska, Forente stater, 68516
- Rekruttering
- Research Site
-
Omaha, Nebraska, Forente stater, 68114
- Rekruttering
- Research Site
-
-
New Jersey
-
Newark, New Jersey, Forente stater, 07103
- Rekruttering
- Research Site
-
Newark, New Jersey, Forente stater, 07103
- Har ikke rekruttert ennå
- Research Site
-
Northfield, New Jersey, Forente stater, 08225
- Rekruttering
- Research Site
-
Ocean City, New Jersey, Forente stater, 07712
- Rekruttering
- Research Site
-
Paramus, New Jersey, Forente stater, 07652
- Rekruttering
- Research Site
-
-
New Mexico
-
Albuquerque, New Mexico, Forente stater, 87106
- Rekruttering
- Research Site
-
-
New York
-
Albany, New York, Forente stater, 12208
- Rekruttering
- Research Site
-
Cortland, New York, Forente stater, 13045
- Rekruttering
- Research Site
-
Hawthorne, New York, Forente stater, 10532
- Rekruttering
- Research Site
-
Hollis, New York, Forente stater, 11423
- Tilbaketrukket
- Research Site
-
New York, New York, Forente stater, 10032
- Rekruttering
- Research Site
-
New York, New York, Forente stater, 11355
- Rekruttering
- Research Site
-
New York, New York, Forente stater, 10019
- Tilbaketrukket
- Research Site
-
Rochester, New York, Forente stater, 14607
- Fullført
- Research Site
-
The Bronx, New York, Forente stater, 10459
- Rekruttering
- Research Site
-
The Bronx, New York, Forente stater, 10461
- Rekruttering
- Research Site
-
Vestal, New York, Forente stater, 13850
- Rekruttering
- Research Site
-
Vestal, New York, Forente stater, 13850
- Tilbaketrukket
- Research Site
-
Watertown, New York, Forente stater, 13601
- Rekruttering
- Research Site
-
-
North Carolina
-
Charlotte, North Carolina, Forente stater, 28277
- Tilbaketrukket
- Research Site
-
Durham, North Carolina, Forente stater, 27705
- Har ikke rekruttert ennå
- Research Site
-
-
Ohio
-
Cincinnati, Ohio, Forente stater, 45229
- Har ikke rekruttert ennå
- Research Site
-
Columbus, Ohio, Forente stater, 43205
- Har ikke rekruttert ennå
- Research Site
-
Columbus, Ohio, Forente stater, 43228
- Rekruttering
- Research Site
-
Dayton, Ohio, Forente stater, 45424
- Rekruttering
- Research Site
-
Findlay, Ohio, Forente stater, 45840
- Rekruttering
- Research Site
-
Toledo, Ohio, Forente stater, 43617
- Rekruttering
- Research Site
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Forente stater, 73120
- Rekruttering
- Research Site
-
Oklahoma City, Oklahoma, Forente stater, 73104
- Rekruttering
- Research Site
-
Oklahoma City, Oklahoma, Forente stater, 73104
- Har ikke rekruttert ennå
- Research Site
-
Yukon, Oklahoma, Forente stater, 73099
- Rekruttering
- Research Site
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Forente stater, 15241
- Rekruttering
- Research Site
-
-
South Carolina
-
Charleston, South Carolina, Forente stater, 29425
- Rekruttering
- Research Site
-
Rock Hill, South Carolina, Forente stater, 29730
- Fullført
- Research Site
-
-
South Dakota
-
Sioux Falls, South Dakota, Forente stater, 57105
- Rekruttering
- Research Site
-
-
Tennessee
-
Nashville, Tennessee, Forente stater, 37232
- Rekruttering
- Research Site
-
-
Texas
-
Austin, Texas, Forente stater, 78759
- Rekruttering
- Research Site
-
Baytown, Texas, Forente stater, 77521
- Rekruttering
- Research Site
-
Beaumont, Texas, Forente stater, 77701
- Rekruttering
- Research Site
-
Beaumont, Texas, Forente stater, 77702
- Rekruttering
- Research Site
-
Bellaire, Texas, Forente stater, 77401
- Rekruttering
- Research Site
-
Corpus Christi, Texas, Forente stater, 78411
- Rekruttering
- Research Site
-
Corsicana, Texas, Forente stater, 75110
- Rekruttering
- Research Site
-
Dallas, Texas, Forente stater, 75231
- Rekruttering
- Research Site
-
Dallas, Texas, Forente stater, 75235
- Rekruttering
- Research Site
-
El Paso, Texas, Forente stater, 79912
- Rekruttering
- Research Site
-
Frisco, Texas, Forente stater, 75034
- Tilbaketrukket
- Research Site
-
Houston, Texas, Forente stater, 77099
- Rekruttering
- Research Site
-
Houston, Texas, Forente stater, 77030
- Har ikke rekruttert ennå
- Research Site
-
Houston, Texas, Forente stater, 77065
- Rekruttering
- Research Site
-
Kerrville, Texas, Forente stater, 78028
- Tilbaketrukket
- Research Site
-
McKinney, Texas, Forente stater, 75069
- Rekruttering
- Research Site
-
San Antonio, Texas, Forente stater, 78229
- Rekruttering
- Research Site
-
San Antonio, Texas, Forente stater, 78215
- Rekruttering
- Research Site
-
San Antonio, Texas, Forente stater, 78249
- Har ikke rekruttert ennå
- Research Site
-
Tyler, Texas, Forente stater, 75708
- Fullført
- Research Site
-
-
Utah
-
West Jordan, Utah, Forente stater, 84088
- Rekruttering
- Research Site
-
-
Vermont
-
Burlington, Vermont, Forente stater, 05405
- Rekruttering
- Research Site
-
-
Virginia
-
Burke, Virginia, Forente stater, 22015
- Tilbaketrukket
- Research Site
-
-
Washington
-
Bellingham, Washington, Forente stater, 98225
- Fullført
- Research Site
-
Vancouver, Washington, Forente stater, 98664
- Rekruttering
- Research Site
-
-
-
-
-
Beijing, Kina, 100191
- Rekruttering
- Research Site
-
Beijing, Kina, 100050
- Rekruttering
- Research Site
-
Bengbu, Kina, 233004
- Rekruttering
- Research Site
-
Chengdu, Kina, 610066
- Rekruttering
- Research Site
-
Chongqing, Kina, 401122
- Rekruttering
- Research Site
-
Hohhot, Kina, 10050
- Rekruttering
- Research Site
-
Mianyang, Kina, 621000
- Rekruttering
- Research Site
-
Shanghai, Kina, 200433
- Rekruttering
- Research Site
-
Shanghai, Kina
- Rekruttering
- Research Site
-
Shanghai, Kina, 200062
- Rekruttering
- Research Site
-
Shantou, Kina, 515041
- Rekruttering
- Research Site
-
Shenyang, Kina, 110004
- Rekruttering
- Research Site
-
Shenzhen, Kina, 518026
- Rekruttering
- Research Site
-
Suzhou, Kina, 215002
- Rekruttering
- Research Site
-
Taizhou, Kina, 318000
- Rekruttering
- Research Site
-
Tianjin, Kina, 300211
- Rekruttering
- Research Site
-
Tianjin, Kina, 300134
- Rekruttering
- Research Site
-
Tianjin, Kina, 300050
- Rekruttering
- Research Site
-
Wuhan, Kina, 430000
- Rekruttering
- Research Site
-
Yanji, Kina, 133000
- Rekruttering
- Research Site
-
Yantai, Kina, 264000
- Rekruttering
- Research Site
-
Zhongshan, Kina, 528400
- Rekruttering
- Research Site
-
-
-
-
-
Chihuahua City, Mexico, 31000
- Rekruttering
- Research Site
-
Chihuahua City, Mexico, 31238
- Rekruttering
- Research Site
-
Guadalajara, Mexico, 44100
- Rekruttering
- Research Site
-
Guadalajara, Mexico, 44500
- Rekruttering
- Research Site
-
Monterrey, Mexico, 64465
- Rekruttering
- Research Site
-
-
-
-
-
Durban, Sør-Afrika, 4001
- Rekruttering
- Research Site
-
Durban, Sør-Afrika, 3630
- Rekruttering
- Research Site
-
Durban, Sør-Afrika, 4092
- Rekruttering
- Research Site
-
Krugersdorp, Sør-Afrika, 1739
- Rekruttering
- Research Site
-
Middelburg, Sør-Afrika, 1055
- Rekruttering
- Research Site
-
Panorama, Sør-Afrika, 7500
- Rekruttering
- Research Site
-
Somerset West, Sør-Afrika, 7130
- Har ikke rekruttert ennå
- Research Site
-
Welkom, Sør-Afrika, 9460
- Rekruttering
- Research Site
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
-
Confirmed clinical diagnosis of asthma at least 12 months.
-
Receiving one of the following scheduled asthma maintenance therapies for at least 3 months with stable dosing for at least the last one month
- Low-to-high-dose Inhaled corticosteroid(s) (ICS)
- Low-to-high-dose ICS or ICS/long-acting β2-agonist (LABA) with or without one additional maintenance therapy from the following: leukotriene receptor antagonist (LTRA), long-acting muscarinic antagonist (LAMA), or theophylline
-
Receiving inhaled short-acting β2-agonist (SABA) as needed.
-
A documented history of at least one severe asthma exacerbation within 12 months.
-
Use of Sponsor-provided albuterol sulfate inhalation aerosol medication.
-
Demonstrate acceptable MDI administration technique as assessed by the investigator; use of spacers is prohibited.
-
Able to perform acceptable and reproducible peak expiratory flow (PEF) measurements as assessed by the investigator.
-
Participants must adhere to protocol specific contraception methods.
-
Negative urine pregnancy test for participants of childbearing potential.
-
Have a BMI < 40 kg/ m^2.
-
Capable of giving assent (signing the assent form) to participate in the study which includes compliance with the requirements and restrictions. The caregiver of the patient must be capable of giving written informed consent for the patient's participation in the study. Consent and assent forms must be completed prior to any study-specific procedures.
Exclusion Criteria:
- Life-threatening asthma defined as any history of significant asthma episode(s) requiring intubation associated with hypercapnia, respiratory arrest, hypoxic seizures, or asthma-related syncopal episode(s).
- Experienced > 3 severe asthma exacerbations within 12 months before screening.
- Completed treatment for lower respiratory infection and severe asthma exacerbation with SCS within 4 weeks of screening.
- Upper respiratory infection involving antibiotic treatment not resolved.
- Current smokers, former smokers with > 10 pack-years history, or former smokers who stopped smoking < 6 months (including all forms of tobacco, e-cigarettes [vaping], and marijuana).
- Other significant lung disease, including regular or occasional use of oxygen.
- Historical or current evidence of a clinically significant disease including, but not limited to: cardiovascular, hepatic, renal, hematological, neuropsychological, endocrine, or gastrointestinal disorders.
- Cancer not in complete remission for at least 5 years.
- History or hospitalization for psychiatric disorder or attempted suicide within one year.
- Significant abuse of alcohol or drugs, in the opinion of the investigator.
- Oral corticosteroid(s) (OCS)/SCS use (any dose and any indication) within 4 weeks before Visit 1 or chronic use of OCS/SCS (≥ 3 weeks use in 3 months prior to Visit 1).
- Use of any oral SABAs within one month.
- Having a known or suspected hypersensitivity to albuterol/salbutamol, or budesonide and/or their excipients.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Budesonide/albuterol metered -dose inhaler (BDA MDI)
Participants will receive BDA MDI 160/180 μg (given as 2 puffs of 80/90 μg) as needed. |
Participants will receive oral inhalation of BDA MDI 160/180 μg taken as 2 puffs of 80/90 μg as needed.
Andre navn:
|
|
Aktiv komparator: Albuterol sulfate metered-dose inhaler (AS MDI)
Participants will receive AS MDI 180 μg (given as 2 puffs of 90 μg) as needed. |
Participants will receive oral inhalation of AS MDI 180 μg taken as 2 puffs of 90 μg as needed.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Annualized rate of severe asthma exacerbations (AAER)
Tidsramme: From Randomization (Day 1) to Week 52 (EOT)
|
The effect of BDA MDI compared with AS MDI, both administered as needed, on the AAER in participants with asthma will be evaluated. |
From Randomization (Day 1) to Week 52 (EOT)
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Time to first (TTF) severe asthma exacerbation
Tidsramme: From Randomization (Day 1) to Week 52 (EOT)
|
The effect of BDA MDI compared with AS MDI, both administered as needed, on the risk of a first severe asthma exacerbation in participants with asthma will be evaluated. |
From Randomization (Day 1) to Week 52 (EOT)
|
|
Annualized total systemic corticosteroids (SCS) exposure for treatment of asthma
Tidsramme: From Randomization (Day 1) to Week 52 (EOT)
|
The effect of BDA MDI compared with AS MDI, both administered as needed, on the annualized total SCS exposure for treatment of asthma in participants with asthma will be evaluated. |
From Randomization (Day 1) to Week 52 (EOT)
|
|
Number of participants with adverse events (AEs) and severe adverse events (SAEs)
Tidsramme: Up to Week 52
|
The safety and tolerability of BDA MDI compared with AS MDI in participants with asthma will be assessed. |
Up to Week 52
|
|
Maximum Observed Concentration (Cmax)
Tidsramme: At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized. |
At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
|
Area under concentration-time curve from time 0 to last quantifiable concentration (AUClast)
Tidsramme: At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized. |
At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
|
Area under concentration-time curve from time 0 to infinity (AUCinf)
Tidsramme: At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized. |
At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
|
Time to reach maximum concentration following drug administration (Tmax)
Tidsramme: At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized. |
At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
|
Time of last quantifiable concentration (Tlast)
Tidsramme: At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized. |
At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
|
Terminal elimination half-life (t½λz)
Tidsramme: At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized. |
At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
|
Terminal elimination rate constant (λz)
Tidsramme: At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized. |
At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
|
Apparent total body clearance (CL/F)
Tidsramme: At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized. |
At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
|
Apparent volume of distribution based on the terminal phase (Vz/F)
Tidsramme: At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized. |
At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- D6934C00001
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
"Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.
IPD-delingstidsramme
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Tilgangskriterier for IPD-deling
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non negotiable contract for data accessors) must be in place before accessing requested information.
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- SEVJE
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .